Drug Profile
Research programme: COVID-2019 vaccines - HaloVax/Massachusetts General Hospital
Alternative Names: HaloVax™ - HaloVax/Massachusetts General Hospital; SAV - HaloVax/Massachusetts General Hospital; Self-Assembling Vaccine - HaloVax/Massachusetts General HospitalLatest Information Update: 17 Jun 2021
Price :
$50
*
At a glance
- Originator HaloVax; Massachusetts General Hospital
- Class COVID-19 vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 17 Jun 2021 Hoth Therapeutics announces intention to complete IND-enabling studies in 2021
- 09 Feb 2021 Voltron Therapeutics initiates preclinical studies for COVID-2019 infections (Prevention) in USA (Parenteral)
- 09 Feb 2021 Voltron Therapeutics initiates preclinical studies for COVID-2019 infections in USA (Parenteral)